surmount-1 tirzepatide trial obesity without diabetes SURMOUNT-4 results just published in

Results Patient Baseline Characteristics Overall, a total of 9916 patients met the eligibility criteria and were included in the study

In practice, this means compounding pharmacies have pivoted to formulations that include additional ingredients, like glycine, to differentiate their products from brand-name Mounjaro and Zepbound

Give 15% off, earn 10% back on every order they place

Zepbound un farmaco pensato per favorire il dimagrimento, a base di tirzepatide

It is worth the effort

The agency continues to require the manufacturer, Eli Lilly, to conduct post-marketing studies, including the SURPASS-CVOT cardiovascular outcomes trial, which will provide extended safety data on over 12,500 patients